Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Jan L Fisher"'
Autor:
Adrian Schwarzer, Benita Wolf, Jan L Fisher, Thomas Schwaab, Sven Olek, Udo Baron, Craig R Tomlinson, John D Seigne, Nancy A Crosby, Jiang Gui, Thomas H Hampton, Camilo E Fadul, John A Heaney, Marc S Ernstoff
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e46600 (2012)
PurposeTo evaluate CD4(+)CD25(+)FOXP3(+) T regulatory cells (T(REG)) and associated immune-regulatory pathways in peripheral blood lymphocytes (PBL) of metastatic renal cell carcinoma (mRCC) patients and healthy volunteers. We subsequently investigat
Externí odkaz:
https://doaj.org/article/aad50d9d301d4c0fa7552b1ae4b4d3a9
Autor:
Benita Wolf, Adrian Schwarzer, Anik L Côté, Thomas H Hampton, Thomas Schwaab, Eduardo Huarte, Craig R Tomlinson, Jiang Gui, Jan L Fisher, Camilo E Fadul, Joshua W Hamilton, Marc S Ernstoff
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50221 (2012)
Lymphocytes are a key component of the immune system and their differentiation and function are directly influenced by cancer. We examined peripheral blood lymphocyte (PBL) gene expression as a biomarker of illness and treatment effect using the Affy
Externí odkaz:
https://doaj.org/article/af3c24e12d5f46098ea62100b0e554fb
Autor:
Jan L. Fisher, Marc S. Ernstoff, Keisuke Shirai, Fred W. Kolling, Mary Jo Turk, Shaofeng Yan, Christina V. Angeles, Jichang Han, Aleksey K. Molodtsov, Tyler G. Searles, Justin M. Bader, Yanding Zhao, Peisheng Zhang, Chao Cheng, Jiang Gui
Publikováno v:
Nat Cancer
While T-cell responses to cancer immunotherapy have been avidly studied, long-lived memory has been poorly characterized. In a cohort of metastatic melanoma survivors with exceptional responses to immunotherapy, we probed memory CD8+ T-cell responses
Autor:
Marc S. Ernstoff, Jared E. Lopes, Heather L. Flick, Heather C. Losey, Jan L. Fisher, Chunhua Wang, Lei Sun, Juan C. Alvarez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundInterleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4+and CD8+T cells, and regulatory T cells (Tregs). Low concentration
Autor:
Brock C. Christensen, Alissa A. Thomas, Arti B. Gaur, Marc S. Ernstoff, Gilbert J. Rahme, Camilo E. Fadul, Sandra E. Steel, Chery A. Whipple, Melissa C. Davis, Thomas H. Hampton, Jan L. Fisher, Lionel D. Lewis, Gregory J. Tsongalis
Publikováno v:
Cancer Immunology, Immunotherapy. 66:379-389
Vascular endothelial growth factor (VEGF), in addition to being pro-angiogenic, is an immunomodulatory cytokine systemically and in the tumor microenvironment. We previously reported the immunomodulatory effects of radiation and temozolomide (TMZ) in
Autor:
Zhongze Li, Jan L. Fisher, Jiang Gui, Gregory D. Seidel, Britt M. Holderness, Marc S. Ernstoff, Shaofeng Yan
Publikováno v:
Anticancer Research. 36:6449-6456
E-Cadherin and N-cadherin are important components of epithelial–mesenchymal transition (EMT). The majority of studies on EMT in melanoma have been performed with cultured cell lines or pooled melanoma samples. The goal of our study was to evaluate
Autor:
Jan L. Fisher, Christina V. Angeles, Mary Jo Turk, Marc S. Ernstoff, Chao Cheng, Shaofeng Yan, Lawrence F. Kuklinski, Zhongze Li, Randolph J. Noelle
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(7)
Adaptive immune responses contribute to the pathogenesis of melanoma by facilitating immune evasion. V-domain Ig suppressor of T-cell activation (VISTA) is a potent negative regulator of T-cell function and is expressed at high levels on monocytes, g
Autor:
Alissa A. Thomas, Jan L. Fisher, Francine B. de Abreu, Michael B. Miller, C. Harker Rhodes, Joel A. Lefferts, Gilbert J. Rahme, Thomas H. Hampton, Chery A. Whipple, Camilo E. Fadul, Laura J. Tafe, Jonathan K. Kleen, Gregory J. Tsongalis, Heather A. Wishart, Tim Schwachula, Sven Olek, Marc S. Ernstoff, Udo Baron, Jiang Gui
Publikováno v:
Neuro-Oncology. 17:801-809
Immunotherapy is emerging as an effective new treatment for many cancers,1 but it has yet to translate into a proven clinical benefit for patients with glioblastoma.2 A purported limitation of applying immunotherapy to gliomas is the tumor-induced im
Autor:
Tong Zhang, Claire Godbersen, Marc S. Ernstoff, Tiffany A. Coupet, Amelia M. Huehls, Jan L. Fisher, Charles L Sentman, Michael B. Battles
Publikováno v:
Molecular cancer therapeutics. 16(7)
Two new bispecific T-cell engaging (BiTE) molecules with specificity for NKG2D ligands were developed and functionally characterized. One, huNKG2D-OKT3, was derived from the extracellular portion of the human NKG2D receptor fused to a CD3ϵ binding s
Autor:
Diane Mellinger, Laura J. Tafe, Jan L. Fisher, Gregory J. Tsongalis, Marc S. Ernstoff, Thomas H. Hampton, Camilo E. Fadul, Andrea Boni, Shaofeng Yan, Chery A. Whipple, Mary Jo Turk, David W. Mullins, Constance E. Brinckerhoff
Publikováno v:
Melanoma research. 26(3)
The advent of drugs targeting the mitogen-activated protein kinase (MAPK) pathway has markedly changed the treatment of advanced-stage melanoma harboring BRAF mutations. However, drug resistance, through mechanisms not well elucidated, often occurs.